not specific Archives - TBC repository

A scoping literature review is underway to identify key principles and strategies from existing vaccine allocation frameworks. The review focuses on vaccines utilized in routine and emergency contexts, including malaria, COVID-19, dengue, and meningococcal vaccines, among others.

Global TB vaccine partnership

2011-2023

The Global Tuberculosis Vaccine Partnership (GTBVP) is a forum for key stakeholders in TB vaccine R&D to identify and address barriers impeding TB vaccine R&D and to discuss R&D priorities in order to help inform funding decisions

Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how?

Hypothetical vaccines

Tuberculosis is the leading bacterial cause of death globally. In 2021, 10·6 million people developed symptomatic tuberculosis and 1·6 million died. Seven promising vaccine candidates that aim to prevent tuberculosis disease in adolescents and adults are currently in late-stage clinical trials. Conventional phase 3 trials provide information on the direct protection conferred against infection or disease in vaccinated individuals, but they tell us little about possible indirect (ie, transmission-reducing) effects that afford protection to unvaccinated individuals. As a result, proposed phase 3 trial designs will not provide key information about the overall effect of introducing a vaccine programme. Information on the potential for indirect effects can be crucial for policy makers deciding whether and how to introduce tuberculosis vaccines into immunisation programmes. We describe the rationale for measuring indirect effects, in addition to direct effects, of tuberculosis vaccine candidates in pivotal trials and lay out several options for incorporating their measurement into phase 3 trial designs

An effective vaccine is only the first step: the need to create and sustain demand for TB vaccines

Understanding public willingness to receive new TB vaccines, as well as defining how to address any barriers to acceptance, will be key to ensuring that the promise of these vaccines can be fully realized. Although we can learn from previous vaccine intro ductions, it is imperative we close key research gaps specific to new TB vaccines. This will inform the development of interventions to generate and sustain high demand for TB vaccines in communities that stand to benefit the most

Innovative Financing for TB vaccine R&D

T20 policy brief

Lessons from a decade of adult vaccine rollout in low- and middle-income countries: A scoping review

This paper synthesizes the insights and lessons learned from different vaccine introductions among adult populations in LMICs from the last decade (i.e., 2013 to 2023).

The full value of vaccine assessments concept—current opportunities and recommendations

2024

Building on the success of the recent applications of the FVVA framework, we see important new opportunities to maximize the future utility of FVVAs to country and global stakeholders and provide a proof-of-concept for analyses in other areas of disease control and prevention.

TB vaccine advocacy fellowship

An urgent call for increased global investment and political support for TB vaccine R&D. With the United Nations High-Level Meeting on TB taking place on 22 September 2023, this call will play an important part in amplifying the voices of the global TB community in demanding new TB vaccines. This letter is also in direct support of the recently launched call to action ‘Deadly Divide: Priorities to Close the Deadly Divide’ from the Stop TB Partnership community and non-governmental organization delegations.

TB vaccine advocacy roadmap

2021